Edition:
United Kingdom

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

2.49USD
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
$2.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
207,291
52-wk High
$36.25
52-wk Low
$1.70

Latest Key Developments (Source: Significant Developments)

Altimmune Announces Closing Of Acquisition Of Spitfire Pharma Inc
Monday, 15 Jul 2019 

July 15 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES CLOSING OF ACQUISITION OF SPITFIRE PHARMA, INC..  Full Article

Altimmune To Acquire Spitfire Pharma
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Altimmune Inc ::ALTIMMUNE SIGNS DEFINITIVE AGREEMENT TO ACQUIRE SPITFIRE PHARMA, INC. ADDING NASH DRUG CANDIDATE TO PORTFOLIO.ALTIMMUNE INC - SPITFIRE SHAREHOLDERS WILL RECEIVE AN UPFRONT PAYMENT OF $5 MILLION IN ALTIMMUNE COMMON STOCK.ALTIMMUNE INC - ALTIMMUNE PLANS TO ADVANCE DRUG CANDIDATE INTO CLINIC DURING 2020.ALTIMMUNE INC - SPITFIRE SHAREHOLDERS WILL BE ELIGIBLE TO RECEIVE AN ADDITIONAL $8 MILLION IN FUTURE REGULATORY AND CLINICAL MILESTONES.ALTIMMUNE INC - SPITFIRE SHAREHOLDERS ARE ALSO ELIGIBLE TO RECEIVE UP TO $80 MILLION IN SALES-BASED MILESTONES..ALTIMMUNE INC - TO RECEIVE RIGHTS TO NOVEL GLP-1/GLUCAGON DUAL AGONIST THAT ADDRESSES OBESITY AND METABOLIC DYSFUNCTION.  Full Article

Altimmune Reports Q1 Loss Per Share $0.27
Tuesday, 14 May 2019 

May 14 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE.Q1 LOSS PER SHARE $0.27.Q1 REVENUE $2.96 MILLION VERSUS $2.69 MILLION.CASH, RESTRICTED CASH AND CASH EQUIVALENTS OF $44.9 MILLION AT MARCH 31, 2019.  Full Article

Altimmune Q3 Revenue $2.6 Million Versus $4.6 Million
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 REVENUE $2.6 MILLION VERSUS $4.6 MILLION.QTRLY LOSS PER SHARE $1.73.  Full Article

Altimmune Says Board Approved One-For-Thirty Reverse Stock Split Of Co's Shares
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Altimmune Inc ::ALTIMMUNE - ON SEPT 7, BOARD APPROVED IMPLEMENTATION OF A ONE-FOR-THIRTY (1:30) REVERSE STOCK SPLIT OF CO'S SHARES- SEC FILING.ALTIMMUNE INC - CO'S CONSOLIDATED COMMON STOCK WILL BEGIN TRADING ON NASDAQ GLOBAL MARKET ON A SPLIT-ADJUSTED BASIS ON SEPT 14.  Full Article

Altimmune Files To Say Offering About 58 Mln Common Units
Friday, 17 Aug 2018 

Aug 17 (Reuters) - Altimmune Inc ::ALTIMMUNE FILES TO SAY OFFERING ABOUT 58 MILLION COMMON UNITS, EACH UNIT MADE OF 1 SHARE OF COMMON STOCK & A WARRANT TO PURCHASE 1 SHARE OF COMMON STOCK.  Full Article

Altimmune Announces Financial Results For Year Ended Dec 31
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2017 AND PROVIDES CORPORATE UPDATE.ALTIMMUNE - AT DECEMBER 31, 2017, HAD CASH, CASH EQUIVALENTS, AND RESTRICTED CASH OF APPROXIMATELY $12.3 MILLION.  Full Article

Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune
Friday, 2 Feb 2018 

Feb 2 (Reuters) - Hudson Bay Capital Management LP ::HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING.  Full Article

Altimmune Elects Mitchel Sayare As Chairman Of Its Board
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Altimmune Inc ::ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS.ALTIMMUNE INC - BOARD'S CURRENT CHAIRMAN, DAVID DRUTZ WILL REMAIN ON AS CHAIRMAN OF COMPENSATION COMMITTEE AND MEMBER OF BOARD.  Full Article

Altimmune reports Q3 loss per share $2.05
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Altimmune Inc :Altimmune announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $2.05.Q3 preliminary loss per share $0.34 excluding items.Altimmune Inc qtrly revenue and grants and contracts were $4.6 million versus $0.9 million​.Altimmune Inc - ‍at september 30, 2017, company had cash and cash equivalents of approximately $17.1 million​.Altimmune Inc - ‍initiated a phase 2 clinical trial with nasovax vaccine with initial data expected in q1 2018​.  Full Article

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, banks, oil stocks, Big Lots, Exxon Mobil, DropCar

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes fell on Friday, after data showed U.S. job growth almost stalled in February, adding to concerns of a slowdown in global growth sparked by weak China export data and a prolonged slowdown in the eurozone. At 11:42 ET, the Dow Jones Industrial Average was down 0.45 percent at 25,358.99